TG Therapeutics to Participate in the Evercore HealthCONx Conference
TG Therapeutics (NASDAQ: TGTX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The event will be held at the Loews Coral Gables Hotel in Florida from December 3-5, 2024. Michael S. Weiss, the Company's Chairman and CEO, will participate in a fireside chat on Tuesday, December 3, at 10:00 AM ET. Interested parties can access a live webcast of the discussion through the Events page in the Investors & Media section of the company's website.
TG Therapeutics (NASDAQ: TGTX) ha annunciato la sua partecipazione alla 7ª Conferenza Annuale Evercore HealthCONx. L'evento si svolgerà presso il Loews Coral Gables Hotel in Florida dal 3 al 5 dicembre 2024. Michael S. Weiss, Presidente e CEO dell'azienda, parteciperà a una chiacchierata informale martedì 3 dicembre, alle 10:00 ET. Le parti interessate possono accedere a una diretta web della discussione attraverso la pagina Eventi nella sezione Investitori e Media del sito web della società.
TG Therapeutics (NASDAQ: TGTX) ha anunciado su participación en la 7ª Conferencia Anual Evercore HealthCONx. El evento se celebrará en el Loews Coral Gables Hotel en Florida del 3 al 5 de diciembre de 2024. Michael S. Weiss, Presidente y CEO de la empresa, participará en una charla informal el martes 3 de diciembre a las 10:00 AM ET. Las partes interesadas pueden acceder a una transmisión en vivo de la discusión a través de la página de Eventos en la sección de Inversores y Medios del sitio web de la empresa.
TG Therapeutics (NASDAQ: TGTX)는 제7회 Evercore HealthCONx 컨퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2024년 12월 3일부터 5일까지 플로리다의 로우스 코랄 게이بل스 호텔에서 열립니다. 마이클 S. 웨이스 회사 회장 겸 CEO는 12월 3일 화요일 오전 10시에 진행되는 대화에 참여할 예정입니다. 관심 있는 당사자는 회사 웹사이트의 투자자 및 미디어 섹션의 이벤트 페이지를 통해 토론의 실시간 웹캐스트에 접근할 수 있습니다.
TG Therapeutics (NASDAQ: TGTX) a annoncé sa participation à la 7ème Conférence Annuelle Evercore HealthCONx. L'événement se tiendra au Loews Coral Gables Hotel en Floride du 3 au 5 décembre 2024. Michael S. Weiss, Président et CEO de l'entreprise, participera à une discussion informelle le mardi 3 décembre à 10h00 ET. Les parties intéressées peuvent accéder à un webcast en direct de la discussion via la page Événements dans la section Investisseurs et Médias du site web de l'entreprise.
TG Therapeutics (NASDAQ: TGTX) hat seine Teilnahme an der 7. jährlichen Evercore HealthCONx-Konferenz bekannt gegeben. Die Veranstaltung findet vom 3. bis 5. Dezember 2024 im Loews Coral Gables Hotel in Florida statt. Michael S. Weiss, der Vorstandsvorsitzende und CEO des Unternehmens, wird am Dienstag, den 3. Dezember, um 10:00 Uhr ET an einem Gespräch teilnehmen. Interessierte können über die Veranstaltungsseite im Bereich Investoren & Medien auf die Live-Webcast-Diskussion auf der Unternehmenswebsite zugreifen.
- None.
- None.
Fireside chat scheduled for Tuesday, December 3, 2024, at 10:00 AM ET
NEW YORK, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 7th Annual Evercore HealthCONx Conference, being held at the Loews Coral Gables Hotel, in Florida on December 3-5, 2024. The fireside chat is scheduled to take place on Tuesday, December 3, at 10:00 AM ET.
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) presenting at the Evercore HealthCONx Conference 2024?
Where can I watch TG Therapeutics' (TGTX) Evercore HealthCONx Conference presentation?
Where is the 2024 Evercore HealthCONx Conference being held?
